Replies to post #194419 on Biotech Values

[DewDiligence]

ESPR +8%/AH on FDA assurance that completed CVOT not needed for ETC-1002 to get a “PCSK9-like” label—i.e. HePH + secondary prevention in patients with high risk and inability to get to LDL goal on statins alone:

http://finance.yahoo.com/news/esperion-therapeutics-provides-etc-1002-200500070.html

CC at 4:30pm ET.